Balanced Outlook on Ashland: Near-Term Caution Offset by Longer-Term Upside Potential

Steven Haynes, an analyst from Morgan Stanley, maintained the Hold rating on Ashland. The associated price target was raised to $63.00.

Steven Haynes has given his Hold rating due to a combination of factors, including Ashland’s softer-than-expected first-quarter results and a full-year EBITDA outlook that is now more heavily dependent on a stronger performance in the second half of the fiscal year. He acknowledges that volumes could improve as management anticipates, but he remains cautious, modeling fiscal 2026 EBITDA at the lower end of the company’s guidance range, which tempers the near-term upside.

At the same time, Haynes recognizes a constructive longer-term setup, supported by higher valuation multiples across chemical peers and growth opportunities in Ashland’s high-margin life sciences businesses, such as injectables and film coatings. Potential activist investor involvement also underpins sentiment by offering a possible catalyst, but with no material new developments since the initial 13D filing, he views this as a supportive yet uncertain element, leaving the risk-reward profile balanced rather than compelling enough for a more aggressive rating.

According to TipRanks, Haynes is a 2-star analyst with an average return of 4.5% and a 66.67% success rate.

In another report released on February 4, Evercore ISI also maintained a Hold rating on the stock with a $53.00 price target.